Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,023

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Open access
Konopleva, Marina, Contractor, Rooha, Tsao, Twee, Samudio, Ismael, Ruvolo, Peter P., Kitada, Shinichi, Deng, Xingming, Zhai, Dayong, Shi, Yue-Xi, Sneed, Thomas, Verhaegen, Monique, Soengas, Maria, Ruvolo, Vivian R., McQueen, Teresa, Schober, Wendy D., Watt, Julie C., Jiffar, Tilahun, Ling, Xiaoyang, Marini, Frank C., Harris, David, Dietrich, Martin, Estrov, Zeev, McCubrey, James, May, W. Stratford, Reed, John C., Andreeff, Michael·2006·Cancer Cell
DOI 10.1016/j.ccr.2006.10.006
Open this paper in CoChat — free account

Abstract

BCL-2 proteins are critical for cell survival and are overexpressed in many tumors. ABT-737 is a small-molecule BH3 mimetic that exhibits single-agent activity against lymphoma and small-cell lung cancer in preclinical studies. We here report that ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells. ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. In cells with phosphorylated BCL-2 or increased MCL-1, ABT-737 was inactive. Inhibition of BCL-2 phosphorylation and reduction of MCL-1 expression restored sensitivity to ABT-737. These data suggest that ABT-737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2006.10.006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Andreeff, 1999, Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid, Leukemia, 13, 1881, 10.1038/sj.leu.2401573 · DOI
  2. Bouillet, 1999, Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity, Science, 286, 1735, 10.1126/science.286.5445.1735 · DOI · Paper page
  3. Campos, 1993, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy, Blood, 81, 3091, 10.1182/blood.V81.11.3091.3091 · DOI · Paper page
  4. Certo, 2006, Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, 9, 351, 10.1016/j.ccr.2006.03.027 · DOI · Paper page
  5. Chen, 2005, Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function, Mol. Cell, 17, 393, 10.1016/j.molcel.2004.12.030 · DOI · Paper page
  6. Clohessy, 2006, Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis, J. Biol. Chem., 281, 5750, 10.1074/jbc.M505688200 · DOI
  7. Cory, 2005, Killing cancer cells by flipping the Bcl-2/Bax switch, Cancer Cell, 8, 5, 10.1016/j.ccr.2005.06.012 · DOI · Paper page
  8. Craig, 2002, MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis, Leukemia, 16, 444, 10.1038/sj.leu.2402416 · DOI · Paper page
  9. Deng, 2000, Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases, Proc. Natl. Acad. Sci. USA, 97, 1578, 10.1073/pnas.97.4.1578 · DOI
  10. Deng, 2004, Mono- and multisite phosphorylation enhances Bcl2' antiapoptotic function and inhibition of cell cycle entry functions, Proc. Natl. Acad. Sci. USA, 101, 153, 10.1073/pnas.2533920100 · DOI
  11. Deng, 2006, Bcl2's flexible loop domain regulates p53 binding and survival, Mol. Cell. Biol., 26, 4421, 10.1128/MCB.01647-05 · DOI
  12. Ekert, 2006, Cell death provoked by loss of Interleukin-3 signalling is independent of Bad, Bim, and PI3 Kinase, but depends in part on Puma, Blood, 108, 1461, 10.1182/blood-2006-03-014209 · DOI
  13. Fennell, 2001, In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model, Br. J. Haematol., 112, 706, 10.1046/j.1365-2141.2001.02603.x · DOI
  14. Fesik, 2000, Insights into programmed cell death through structural biology, Cell, 103, 273, 10.1016/S0092-8674(00)00119-7 · DOI · Paper page
  15. Haldar, 1998, Serine-70 is one of the critical sites for drug-induced Bcl-2 phosphorylation in cancer cells, Cancer Res., 58, 1609
  16. Han, 2005, Disruption of MCL-1/BIM complex in granzyme B-mediated mitochondrial apoptosis, J. Biol. Chem., 280, 16383, 10.1074/jbc.M411377200 · DOI
  17. Harada, 2004, Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity, Proc. Natl. Acad. Sci. USA, 101, 15313, 10.1073/pnas.0406837101 · DOI · Paper page
  18. Hsu, 1997, Nonionic detergents induce dimerization among members of the Bcl-2 family, J. Biol. Chem., 272, 13829, 10.1074/jbc.272.21.13829 · DOI · Paper page
  19. Hsu, 1997, Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis, Proc. Natl. Acad. Sci. USA, 94, 3668, 10.1073/pnas.94.8.3668 · DOI · Paper page
  20. Ito, 1997, Bcl-2 phosphorylation required for anti-apoptosis function, J. Biol. Chem., 272, 11671, 10.1074/jbc.272.18.11671 · DOI · Paper page
  21. Jordan, 2000, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells, Leukemia, 14, 1777, 10.1038/sj.leu.2401903 · DOI · Paper page
  22. Kaufmann, 1998, Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse, Blood, 91, 991, 10.1182/blood.V91.3.991.991_991_1000 · DOI · Paper page
  23. Konopleva, 2002, Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentation in acute myelogenous leukemia, Blood, 99, 326, 10.1182/blood.V99.1.326 · DOI
  24. Konopleva, 2005, Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf transformed hematopoietic cells, Cancer Res., 65, 9962, 10.1158/0008-5472.CAN-05-1068 · DOI
  25. Kornblau, 2006, Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia, Blood, 108, 2358, 10.1182/blood-2006-02-003475 · DOI · Paper page
  26. Korsmeyer, 1993, Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death, Semin. Cancer Biol., 4, 327
  27. Kurinna, 2006, Bcl2 phosphorylation and active PKCα are associated with poor survival in AML, Leukemia, 20, 1316, 10.1038/sj.leu.2404248 · DOI
  28. Kuroda, 2006, Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic, Proc. Natl. Acad. Sci. USA, 103, 14907, 10.1073/pnas.0606176103 · DOI · Paper page
  29. Lois, 2002, Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors, Science, 295, 868, 10.1126/science.1067081 · DOI · Paper page
  30. May, 1994, Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis, J. Biol. Chem., 269, 26865, 10.1016/S0021-9258(18)47099-8 · DOI
  31. Milella, 2001, Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia, J. Clin. Invest., 108, 851, 10.1172/JCI12807 · DOI · Paper page
  32. Oh, 2006, A membrane-targeted BID BH3 peptide is sufficient for high potency activation of BAX in vitro, J. Biol. Chem., 10.1074/jbc.M602341200 · DOI
  33. Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579 · DOI · Paper page
  34. Opferman, 2005, Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells, Science, 307, 1101, 10.1126/science.1106114 · DOI · Paper page
  35. Park, 1995, Primitive human hematopoietic precursors express Bcl-x but not Bcl-2, Blood, 86, 868, 10.1182/blood.V86.3.868.868 · DOI
  36. Pellecchia, 2004, Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: New avenues for cancer chemoprevention and chemotherapy, Curr. Pharm. Des., 10, 1387, 10.2174/1381612043384880 · DOI
  37. Puthalakath, 1999, The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex, Mol. Cell, 3, 287, 10.1016/S1097-2765(00)80456-6 · DOI · Paper page
  38. Schubert, 2001, Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis, Biochem. J., 356, 473, 10.1042/0264-6021:3560473 · DOI
  39. Sedlak, 1995, Multiple Bcl-2 family members demonstrate selective dimerizations with Bax, Proc. Natl. Acad. Sci. USA, 92, 7834, 10.1073/pnas.92.17.7834 · DOI · Paper page
  40. Sharpe, 2004, Control of mitochondrial permeability by Bcl-2 family members, Biochim. Biophys. Acta, 1644, 107, 10.1016/j.bbamcr.2003.10.016 · DOI · Paper page
  41. Srivastava, 1998, Involvement of microtubules in the regulation of Bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase, Mol. Cell. Biol., 18, 3509, 10.1128/MCB.18.6.3509 · DOI · Paper page
  42. Tan, 2005, Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy, Cancer Cell, 7, 227, 10.1016/j.ccr.2005.02.008 · DOI · Paper page
  43. Tan, 2006, Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2, J. Biol. Chem., 281, 14764, 10.1074/jbc.M602374200 · DOI
  44. Vaux, 1988, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c- myc to immortalize pre-B cells, Nature, 335, 440, 10.1038/335440a0 · DOI · Paper page
  45. Willis, 2005, Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins, Genes Dev., 19, 1294, 10.1101/gad.1304105 · DOI · Paper page
  46. Wolter, 1997, Movement of Bax from the cytosol to mitochondria during apoptosis, J. Cell Biol., 139, 1281, 10.1083/jcb.139.5.1281 · DOI · Paper page
  47. Zha, 1996, Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2, J. Biol. Chem., 271, 7440, 10.1074/jbc.271.13.7440 · DOI · Paper page
  48. Zhai, 2005, Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak, J. Biol. Chem., 280, 15815, 10.1074/jbc.M411902200 · DOI
  49. Zhou, 2005, Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition, Exp. Cell Res., 309, 316, 10.1016/j.yexcr.2005.06.014 · DOI
  50. Zhu, 2004, Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells, Proc. Natl. Acad. Sci. USA, 101, 7681, 10.1073/pnas.0402293101 · DOI

Cited by

See all 1,023

Metadata

Authors
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., Verhaegen, M., Soengas, M., Ruvolo, V. R., McQueen, T., Schober, W. D., Watt, J. C., Jiffar, T., Ling, X., Marini, F. C., Harris, D., Dietrich, M., Estrov, Z., McCubrey, J., May, W. S., Reed, J. C., & Andreeff, M.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2006-11
Volume
10
Issue
5
Pages
375-388
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/j.ccr.2006.10.006
OpenAlex
W2068962767
Cited by
1,023
References
6
FWCI
20.14
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.